G. Dore, J. Grebely, F. Altice, A.H. Litwin, O. Dalgard, E.J. Gane, . . . H.L. Platt. (2017). O21 HCV reinfection and injecting risk behaviour following elbasvir/grazoprevir treatment in patients on opioid agonist therapy: Co-STAR three year follow-up study. Elsevier.
Chicago Style (17th ed.) CitationG. Dore, et al. O21 HCV Reinfection and Injecting Risk Behaviour Following Elbasvir/grazoprevir Treatment in Patients on Opioid Agonist Therapy: Co-STAR Three Year Follow-up Study. Elsevier, 2017.
MLA (9th ed.) CitationG. Dore, et al. O21 HCV Reinfection and Injecting Risk Behaviour Following Elbasvir/grazoprevir Treatment in Patients on Opioid Agonist Therapy: Co-STAR Three Year Follow-up Study. Elsevier, 2017.
Warning: These citations may not always be 100% accurate.